Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Abstract Background Label-retaining cancer cells (LRCC) have been proposed as a model of slowly cycling cancer stem cells (CSC) which mediate resistance to chemotherapy, tumor recurrence, and metastasis. The molecular mechanisms of chemoresistance in LRCC remain to-date incompletely understood. This...

Full description

Bibliographic Details
Main Authors: Dandan Li, John E. Mullinax, Taylor Aiken, Hongwu Xin, Gordon Wiegand, Andrew Anderson, Snorri Thorgeirsson, Itzhak Avital, Udo Rudloff
Format: Article
Language:English
Published: BioMed Central 2018-07-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Cancer stem cell
Label-retaining cancer cells (LRCC)
PDPK1
Chemoresistance
Online Access:http://link.springer.com/article/10.1186/s12885-018-4690-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4690-1

Similar Items